ENTITY
Shift Bioscience Secures $16M in Seed Funding to Identify Genes for Epigenetic Clock Reversal
Shift Bioscience, Epigenetic Clock, Anti-Aging Research, Seed Funding, British Startup, Genetic Research
Eli Lilly Commits £279 Million to UK Life Sciences Sector in Groundbreaking Partnership
Eli Lilly, UK life sciences, £279 million investment, Lilly Gateway Labs, obesity treatment, UK government partnership
Pfizer Secures Second FDA Approval for Hemophilia Treatment in Six Months
Pfizer, FDA approval, Hemophilia, Gene Therapy, Hemophilia B, HYMPAVZI
Catalent Sells New Jersey Facility and HQ to Ardena, Expanding Belgian CDMO’s US Footprint
Catalent, Ardena, New Jersey manufacturing plant, HQ sale, CDMO expansion, pharmaceutical manufacturing
Evonik Announces Additional Layoffs Amid Ongoing Reorganization
Evonik, layoffs, reorganization, cost reduction, job cuts
Jasper Therapeutics Escalates Dose in Hives Trial Following Rapid Complete Responses
Jasper Therapeutics, briquilimab, chronic inducible urticaria, hives, dose escalation, clinical trial, SPOTLIGHT study
Advancements in Pulmonary Hypertension and Interstitial Lung Disease: Emerging Therapies and Clinical Trial Designs
Pulmonary Hypertension (PH), Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH), Clinical Trials, Emerging Therapies, Pathogenesis, Phenotypes, Diagnostic Tools
Turnstone Biologics Undergoes Strategic Restructuring with Layoffs and Leadership Changes
Turnstone Biologics, layoffs, leadership changes, strategic restructuring, biotech industry
FDA Advisory Committee Supports Stealth BioTherapeutics’ Elamipretide for Barth Syndrome Despite Data Concerns
Stealth BioTherapeutics, elamipretide, Barth syndrome, FDA advisory committee, ultra-rare disease, unmet medical need
Sanofi’s Frexalimab Shows Promise in Multiple Sclerosis with Positive Phase 2 Results
Sanofi, Frexalimab, Multiple Sclerosis, Phase 2 Trial, CD40L Antibody